Welcome to our dedicated page for EVOMMUNE SEC filings (Ticker: EVMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evommune, Inc. (NYSE: EVMN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer. As a public company, Evommune submits reports to the U.S. Securities and Exchange Commission that describe its financial condition, clinical development progress and material corporate events.
Among these documents are current reports on Form 8-K, such as the filing in which Evommune reported issuing a press release with a business update and financial results for a completed quarter. That press release, furnished as an exhibit and incorporated by reference, summarized the status of its lead programs EVO756 and EVO301, clinical milestones, collaboration revenue and cash position. Similar filings can help readers understand how the company presents its pipeline and operations to regulators and investors.
On this page, users can review Evommune’s periodic and current reports, including items that address results of operations and financial condition, risk factor discussions and descriptions of forward-looking statements. These filings often elaborate on topics such as clinical trial design and timing, potential market opportunities for chronic inflammatory disease therapies, and risks related to regulatory approval, competition, intellectual property and collaborations.
Stock Titan enhances access to these SEC documents with AI-powered summaries that highlight key points from long filings, helping users quickly identify sections on clinical programs, financial metrics and material events. The page also updates as new filings are submitted to the SEC’s EDGAR system, allowing investors and researchers to follow Evommune’s regulatory history, including current reports, registration statements and other relevant disclosures.
Evommune, Inc. is a clinical-stage biotechnology company focused on therapies for chronic inflammatory diseases, initially chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its strategy is to target key immune pathways driving mast cell activation, neuroinflammation and cytokine signaling.
The lead oral candidate EVO756 is a highly selective MRGPRX2 antagonist designed to modulate both mast cells and peripheral sensory neurons. Phase 1 data in 132 healthy volunteers showed it was well-tolerated with no serious adverse events and robust pharmacodynamic target engagement in an icatibant-induced skin wheal model. A Phase 2 CIndU trial in 30 patients with symptomatic dermographism showed 70% of 27 observed patients improved on FricTest at four weeks, 30% achieved complete response, and clinically meaningful itch reductions, with no serious adverse events. Phase 2b dose‑ranging trials in CSU and moderate‑to‑severe AD are ongoing, with 12‑week treatment and UAS7 or EASI as primary endpoints.
The second clinical candidate EVO301, in‑licensed from AprilBio, is a long-acting SAFA‑IL‑18 binding protein fusion targeting the IL‑18 pathway. A Phase 2a trial in 70 adults with moderate‑to‑severe AD using two intravenous doses met its primary endpoint, showing clinically meaningful activity and statistically significant improvement over placebo at weeks 4, 8 and 12. Evommune plans a subcutaneous Phase 2b trial in AD and is evaluating additional IL‑18–driven indications such as UC, Crohn’s disease and cardiovascular inflammatory conditions. The company is also preparing a Phase 2b trial of EVO756 in migraine and is advancing preclinical programs in other immunology and inflammation indications.
Evommune, Inc. reported fourth quarter and full year 2025 results and highlighted major clinical and financing milestones. Revenue reached $13.0 million for 2025, up from $7.0 million in 2024, driven by a licensing collaboration for EVO756 in Japan. Research and development expenses were $74.0 million and general and administrative expenses were $20.0 million, leading to a full year net loss of $68.9 million.
As of December 31, 2025, cash, cash equivalents and investments totaled $216.7 million, and together with a subsequent $125 million private placement in February 2026, are expected to fund operations through 2028. The company reported positive Phase 2a proof‑of‑concept data for EVO301 in atopic dermatitis, with meaningful EASI improvements and a favorable safety profile, and is planning a Phase 2b, Phase 3‑enabling trial. Oral MRGPRX2 antagonist EVO756 is in Phase 2b trials in chronic spontaneous urticaria and atopic dermatitis, with top‑line data expected in the second quarter and second half of 2026, and a migraine trial planned for mid‑2026.
Evommune, Inc. received a new investment from LSP 7 through a February 2026 private placement. The company sold 4,494,279 common shares at $27.88 per share to institutional investors, including LSP 7, raising additional equity capital.
LSP 7 purchased 358,680 shares for total consideration of $9,999,998.40 and now beneficially owns 5,288,313 Evommune shares, representing about 14.7% of the 36,018,372 shares outstanding after the closing. LSP 7 Management B.V., a Netherlands entity, is the sole director of LSP 7.
In connection with the transaction, Evommune agreed to file a Form S-1 registration statement to register the resale of the private placement shares within 60 days of the February 17, 2026 closing and to use reasonable best efforts to keep that registration effective until the shares can be freely resold.
Evommune, Inc. director and 10% owner LSP 7 Cooperative UA, through its affiliated entity, acquired 358,680 shares of Common Stock as a grant or award on February 17, 2026 at $27.88 per share. Following this transaction, LSP 7 reported holding 5,288,313 shares indirectly. The shares are held of record by LSP 7 Cooperatief UA, with LSP 7 Management B.V. as sole director; its managing directors may be deemed to share beneficial ownership but each disclaims beneficial ownership of these shares.
Evommune, Inc. reported an insider-related equity award involving an affiliated investment entity. On February 17, 2026, LSP 7 Cooperatief U.A., an entity associated with director and 10% owner Felice Isabel Verduyn-van Weegen, acquired 358,680 shares of common stock at $27.88 per share through a grant or award. Following this transaction, the entity held 5,288,313 common shares indirectly attributed to the reporting person, who disclaims beneficial ownership except to the extent of any pecuniary interest.
Evommune, Inc. received an updated Schedule 13D/A from RA Capital entities and principals Peter Kolchinsky and Rajeev Shah reporting their beneficial ownership of the company’s common stock. The reporting persons collectively report 3,494,638 shares, representing 9.7% of Evommune’s outstanding common stock.
The stake includes 2,710,293 shares held by RA Capital Healthcare Fund, L.P. and 784,345 shares held by RA Capital Nexus Fund III, L.P., over which RA Capital has voting and investment power. As part of a February 2026 private placement totaling 4,494,279 shares at $27.88 per share, the Fund purchased 35,868 shares for $999,999.84.
RA CAPITAL MANAGEMENT, L.P. reported acquisition or exercise transactions in a Form 4 filing for EVMN. The filing lists transactions totaling 35,868 shares at a weighted average price of $27.88 per share. Following the reported transactions, holdings were 2,710,293 shares.
Evommune, Inc. received a Schedule 13G reporting that a group of Nan Fung and Pivotal life sciences investment entities collectively hold a significant minority stake in its common stock. Nan Fung Group Holdings Limited reports beneficial ownership of 3,435,599 shares, or 10.9% of the company’s common stock.
Within the structure, Pivotal bioVenture Partners Fund I directly holds 1,632,441 shares (5.2%), Pivotal bioVenture Partners Fund II holds 294,502 shares (0.9%), and NFLS Delta III holds 1,441,032 shares (4.6%). These percentages are based on 31,524,093 shares outstanding as of December 10, 2025. Voting and investment decisions are made by Nan Fung executive and life sciences committees, while the reporting entities disclaim beneficial ownership of certain smaller individual holdings.
Evommune, Inc. entered into a securities purchase agreement for a private placement of 4,494,279 shares of common stock at $27.88 per share, for expected gross proceeds of about $125 million before expenses. The deal is with a select group of new and existing institutional and healthcare-focused investors and is expected to close on or about February 17, 2026, subject to customary conditions.
Evommune plans to use the net proceeds to advance its clinical development programs and for general corporate purposes. The company also granted investors registration rights, committing to file a Form S-1 to register the resale of these shares and to keep that registration effective until the shares are sold or freely tradable.
Evommune, Inc. reported positive top-line results from a randomized, double-blind, placebo-controlled Phase 2a trial of EVO301 in adults with moderate-to-severe atopic dermatitis. The 70-patient study used two intravenous doses of 5 mg/kg on day 1 and day 28 over 12 weeks.
The trial met its primary endpoint based on a Bayesian analysis of EASI score improvement, with 99.8% of the posterior distribution showing at least an 8% benefit over placebo, far above the 75% success criterion. Using a frequentist method, EVO301 showed statistically significant EASI improvements versus placebo at weeks 4, 8 and 12 with p<0.01.
Placebo-adjusted EASI improvements were 34% at week 8 and 33% at week 12, and 23% of EVO301-treated patients achieved vIGA-AD 0/1 at week 12 compared with 0% on placebo. EVO301 was well tolerated, with no related serious or severe adverse events, no treatment-related discontinuations, and no meaningful safety imbalances. Evommune plans a Phase 2b dose-ranging trial in atopic dermatitis using a subcutaneous formulation and is evaluating additional indications, including ulcerative colitis.